How many stocks are there of Veracyte?
The current number of stocks of Veracyte is 72.64 M undefined.
Veracyte Stocks 2024
Veracyte Stocks
72.64 M
Ticker
VCYT
ISIN
US92337F1075
WKN
A1W7EA
In 2024, Veracyte had 72.64 M outstanding stocks, a 0% change from the 72.64 M stocks in the previous year.
The Veracyte Stocks history
| YEAR | NUMBER OF STOCKS (undefined USD) |
|---|---|
| 2026e | 72.64 |
| 2025e | 72.64 |
| 2024e | 72.64 |
| 2023 | 72.64 |
| 2022 | 71.5 |
| 2021 | 67.9 |
| 2020 | 53.2 |
| 2019 | 46.1 |
| 2018 | 37 |
| 2017 | 33.9 |
| 2016 | 28.8 |
| 2015 | 26 |
| 2014 | 21.6 |
| 2013 | 20.9 |
| 2012 | 20.7 |
| 2011 | 20.7 |
Veracyte shares outstanding US92337F1075 · A1W7EA
The number of shares was Veracyte in 2023 — This indicates how many shares 72.644 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.
3 years
5 years
10 years
25 Years
Max
Number of stocks
Details
Revenue, EBIT and Earnings per share
ⓘRevenue Per Share
Revenue per share represents the total revenue Veracyte earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.
EBIT Per Share
EBIT per share indicates Veracyte's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.
Income Per Share
Income per share, or earnings per share (EPS), reveals the portion of Veracyte’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.
Expected Values
Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Veracyte's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.
| Number of stocks | |
|---|---|
| 2011 | 20.7 M Aktien |
| 2012 | 20.7 M Aktien |
| 2013 | 20.9 M Aktien |
| 2014 | 21.6 M Aktien |
| 2015 | 26 M Aktien |
| 2016 | 28.8 M Aktien |
| 2017 | 33.9 M Aktien |
| 2018 | 37 M Aktien |
| 2019 | 46.1 M Aktien |
| 2020 | 53.2 M Aktien |
| 2021 | 67.9 M Aktien |
| 2022 | 71.5 M Aktien |
| 2023 | 72.64 M Aktien |
| 2024e | 72.64 M Aktien |
| 2025e | 72.64 M Aktien |
| 2026e | 72.64 M Aktien |
Veracyte Aktienanalyse
What does Veracyte do?
Veracyte Inc is a company that specializes in the development and marketing of diagnostic tests for a wide range of diseases and disorders. The company was founded in 2008 and is headquartered in South San Francisco, California. The history of Veracyte Inc begins with the vision to help patients with better diagnostic options. The company has used its expertise in gene expression technology to develop tests that facilitate the diagnosis of diseases and disorders in various areas, such as cancer, thyroid diseases, and lung diseases. Veracyte Inc's business model is based on selling diagnostic tests to healthcare facilities, hospitals, doctors, and other medical institutions. The tests are performed by specially trained professionals and can provide a precise diagnosis that helps doctors plan individualized treatment. Veracyte Inc is divided into different divisions to offer the best and most precise test for each area. The divisions include cancer diagnosis, thyroid diagnostics, lung diagnostics, and other areas of gene expression technology. In cancer diagnosis, Veracyte Inc offers tests for various types of cancer, such as breast cancer, thyroid cancer, and lung cancer. The tests use RNA sequencing to analyze the patient's genetic information and provide a more precise diagnosis. In thyroid diagnostics, Veracyte Inc offers tests for various thyroid diseases that are often difficult to diagnose. The tests help avoid unnecessary surgeries or medical interventions and enable patients to receive a more accurate diagnosis and treatment. In lung diagnostics, Veracyte Inc offers tests for pneumonia, lung cancer, and other lung diseases. The tests use RNA sequencing and imaging to provide accurate diagnoses that help doctors recommend tailored treatment. In addition to these divisions, Veracyte Inc also offers other products and services, such as information campaigns and training for healthcare professionals, as well as support and counseling for patients and their families. Overall, Veracyte Inc aims to revolutionize the medical field and provide patients with better diagnosis and treatment options. The company's tests offer doctors and patients a more precise and personalized diagnosis, allowing for individualized treatment and achieving the best results. Veracyte ist eines der beliebtesten Unternehmen auf Eulerpool.com.Stocks Details
Evaluating Veracyte's Shares Outstanding
Veracyte's shares outstanding refer to the total number of shares that are currently held by all its shareholders, including institutional investors and restricted shares held by the company’s officers and insiders. The number of shares outstanding is crucial in determining the company's market capitalization and is used by investors to assess the company’s size, financial health, and investment potential.
Year-to-Year Comparison
Tracking the changes in Veracyte’s shares outstanding over the years can provide investors with insights into the company's financial strategies and market valuation. An increase in shares outstanding can result from actions like issuing new shares, while a decrease can result from buybacks.
Impact on Investments
For investors, understanding Veracyte’s shares outstanding is essential for evaluating its earnings per share (EPS) and market valuation. A change in the number of shares outstanding can impact the EPS, which is a significant driver of stock prices and investor decisions.
Interpreting Changes in Shares Outstanding
Variances in Veracyte’s shares outstanding can signal shifts in the company’s financial strategy. An increase may dilute the EPS and share value, indicating potential fundraising or acquisitions. Conversely, a decrease, often due to share buybacks, can enhance share value and indicate the company’s confidence in its financial performance.
Frequently Asked Questions about Veracyte stock
What does Number of Shares / OutstandingShares mean?
The outstanding shares (or issued shares) of Veracyte are the total number of shares issued and actively held by shareholders - both external investors and company insiders. However, these must be actual shares. may grant stock options to executives that can be converted into shares.
How has the number of shares of Veracyte evolved in recent years?
The number of shares of Veracyte has increased by 0% gestiegen compared to last year.
What does the number of shares mean for investors?
The number of shares outstanding is used to calculate key metrics such as a company's market capitalization, earnings per share (EPS), and cash flow per share (CFPS). The number of outstanding shares of a company is not static and can fluctuate greatly over time.
Why does the number of stocks fluctuate?
There are various factors that can lead to a change. Veracyte as a company can issue new shares, carry out stock splits or reverse splits.
Does the number of shares have an impact on the performance of Veracyte?
There is no tangible long-term evidence or study that stocks with a certain number of shares (regardless of Mega/Large/Mid/Small Cap) would yield significantly higher returns than others. There are occasional small studies (limited number of stocks, short investment period) that certain classes outperform or have higher risk, but none of them are 1. conclusive (cause-effect is unclear, experiment is not repeatable) or 2. generalizable (generalization is not possible due to small sample size and time period).
How much dividend does Veracyte pay?
Over the past 12 months, Veracyte paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Veracyte is expected to pay a dividend of 0 USD.
What is the dividend yield of Veracyte?
The current dividend yield of Veracyte is .
When does Veracyte pay dividends?
Veracyte pays a quarterly dividend. This is distributed in the months of .
How secure is the dividend of Veracyte?
Veracyte paid dividends every year for the past 0 years.
What is the dividend of Veracyte?
For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.
In which sector is Veracyte located?
Veracyte is assigned to the 'Health' sector.
Wann musste ich die Aktien von Veracyte kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of Veracyte from 8/19/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 8/19/2024.
When did Veracyte pay the last dividend?
The last dividend was paid out on 8/19/2024.
What was the dividend of Veracyte in the year 2023?
In the year 2023, Veracyte distributed 0 USD as dividends.
In which currency does Veracyte pay out the dividend?
The dividends of Veracyte are distributed in USD.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
The Veracyte stock can be added to a savings plan with the following providers: Trade Republic
Andere Kennzahlen von Veracyte
Our stock analysis for Veracyte Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Veracyte Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
